Literature DB >> 8910444

Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts.

G Chen1, S Oh, B P Monia, D W Stacey.   

Abstract

Although members of the RAS protein family (Ha-, Ki-, and N-RAS) are known to play a key role in normal cell proliferation and to be frequently mutated in naturally occurring tumors, it remains unclear which of these proteins functions to regulate growth in normal cells. Gene-specific oligonucleotides (oligos) against c-Ki-RAS (ISIS 6957), c-Ha-RAS (ISIS 2503), and oncogenic Ha-RAS (ISIS 2570) were used to analyze the requirement for individual RAS proteins in the proliferation of diploid human lung fibroblasts (MRC-5), and human bladder carcinoma cell lines with (T24) or without (J-82) a RAS mutation. The oncogenic Ha-RAS oligo substantially inhibited T24 cell proliferation, whereas the c-Ki-RAS and control (ISIS 1966) oligos had little effect. Interestingly, in MRC-5 cells the c-Ki-RAS but not c-Ha-RAS oligo was effective in inhibiting cell proliferation. No inhibition was seen in the J-82 cells with either oligo. In Western analysis, p21 RAS protein was decreased following treatment with the oncogenic Ha-RAS oligo in T24 cells or the c-Ki-RAS oligo in MRC-5 cells, whereas no reductions were observed in J-82 cells with either oligo. The specificity of these oligos was demonstrated in Northern analyses in which both Ha-RAS and Ki-RAS oligo treatment resulted in reduced levels of their respective mRNAs in all three cell lines, whereas the mutant Ha-RAS mRNA in T24 cells was most effectively reduced with the oncogenic Ha-RAS oligo. These results demonstrate that oncogenic Ha-RAS plays an important role in the proliferation of T24 cells, whereas c-Ki-RAS contributes predominantly to the proliferation of normal MRC-5 cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8910444     DOI: 10.1074/jbc.271.45.28259

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  New modalities in oncology: antisense oligonucleotides.

Authors:  C Casey Cunningham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-04

2.  Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma.

Authors:  H J Andreyev; P J Ross; D Cunningham; P A Clarke
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

3.  Ras isoform abundance and signalling in human cancer cell lines.

Authors:  J Omerovic; D E Hammond; M J Clague; I A Prior
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

Review 4.  The p38 MAPK stress pathway as a tumor suppressor or more?

Authors:  Mathew Loesch; Guan Chen
Journal:  Front Biosci       Date:  2008-05-01

Review 5.  Targeting the RAS oncogene.

Authors:  Asami Takashima; Douglas V Faller
Journal:  Expert Opin Ther Targets       Date:  2013-01-30       Impact factor: 6.902

6.  H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells.

Authors:  C Li; R-H Teng; Y-C Tsai; H-S Ke; J-Y Huang; C-C Chen; Y-L Kao; C-C Kuo; W R Bell; B Shieh
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

7.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22

Review 8.  Novel therapies for pancreatic adenocarcinoma.

Authors:  Simona M Pino; Henry Q Xiong; David McConkey; James L Abbruzzese
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.945

Review 9.  Novel therapies for pancreatic adenocarcinoma.

Authors:  Simona M Pino; Henry Q Xiong; David McConkey; James L Abbruzzese
Journal:  Curr Gastroenterol Rep       Date:  2004-04

10.  Identification of a ternary protein-complex as a therapeutic target for K-Ras-dependent colon cancer.

Authors:  Xiaomei Qi; Congying Xie; Songwang Hou; Gang Li; Ning Yin; Lei Dong; Adrienne Lepp; Marla A Chesnik; Shama P Mirza; Aniko Szabo; Susan Tsai; Zainab Basir; Shixiu Wu; Guan Chen
Journal:  Oncotarget       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.